In December 2020, eMed’s proposition involved a small test card and another person on a screen. Abbott supplied the COVID test. A remote guide helped someone use it correctly. The result could then travel beyond the kitchen table as verified information. The interesting invention was the arrangement: take a medical task home, but keep help close enough to make it usable.
- eMed now wraps GLP-1 prescriptions in screening and continuing care.
- Employers buy access; individuals can subscribe directly.
- Aon’s employee program preceded its investment in the company.
- Support has a price. Medication is a separate charge.
01 / The person beside the test
Founded in 2020, eMed counted physician Patrice Harris among its founders. Harris had led the American Medical Association. The company’s early expertise sat between medicine and logistics: getting a test into someone’s hands, guiding its use and making the result useful. At launch, Abbott put the combined test-and-service price at $25.
That division of labor mattered. A test manufacturer makes the instrument. eMed helped organize the encounter. In 2023, its participation in the NIH’s Home Test to Treat program extended the logic toward treatment. A positive result could become the start of care, rather than another loose piece of information for a patient to manage.
“Equitable access to testing and treatment is a core value for us at eMed.”Patrice Harris · 2023
02 / From a moment to a habit
A COVID test is brief. Weight management asks people to return, repeatedly, to treatment and its practical demands. eMed’s present business applies its home-care machinery to that longer relationship. It combines diagnostic screening, clinician-led prescribing, medication access and continuing monitoring. The drug belongs to a pharmaceutical company. The surrounding service is what eMed sells.
The distinction is useful when comparing alternatives. Ro also offers medication access and ongoing provider support. Omada sells employers GLP-1 services with behavioral and clinical care. eMed’s pitch emphasizes home diagnostics and adherence within one managed program. Those are features to examine; they do not, by themselves, establish better results than another provider.
- 01Screen
At home - 02Review
By a clinician - 03Treat
If eligible - 04Support
Keep checking in
Access starts the process. Follow-through keeps the process moving.
03 / The customer who wrote another check
Aon provides the clearest business example. In August 2025, the professional-services firm said more than 1,200 people had registered for its subsidized employee GLP-1 program. Its six-month update reported 95% retention and average weight loss of 22.4 pounds. Aon then announced a strategic investment in eMed.
That sequence is more revealing than a famous face on a website. An employer had tried the benefit with its own workforce before backing the supplier. Still, the figures describe a particular program. Retention is not automatically medication adherence, and a supported, subsidized employee group cannot stand in for every future customer. The result invites investigation rather than closing the argument.
Six-month employee-program update, August 2025. A program-specific observation, not a forecast.
04 / Three lines on the bill
The US consumer offer makes the economics tangible. At the time of review, application and screening cost $49 once. Membership cost $149.99 a month. Prescription medication started at another $149.99 a month, subject to clinical approval. Add the two recurring lines and the advertised starting combination is $299.98 monthly, before the initial screening charge.
The employer route changes who contributes. The CVS Caremark arrangement reported in February 2026 lets employers offer access while choosing their subsidy. It gives a benefits team another choice between funding an expensive benefit in full and offering employees no support. Whether it is attractive depends on the actual contribution and the employee’s remaining bill.
05 / Attention meets distribution
Linda Yaccarino became chief executive in August 2025. Tom Brady joined as founding chief wellness officer and became an investor. In March 2026, eMed announced a $200 million Series A at a valuation above $2 billion. The financing was intended to advance its AI platform and support a new capitated model, bringing another layer of financial responsibility into the proposition.
Distribution is becoming equally consequential. Alight added eMed to its Partner Network in August 2026, opening another route to employer buyers. September brought a women’s-health programming partnership with The Female Quotient. Neither announcement is a patient count. Both show a company trying to reach people through institutions that already have their attention.
06 / Small print, real consequences
The operational details deserve equal billing. A December 2025 inspection of eMed’s UK pharmacy found standards not all met, including confusing website information and incomplete dispensing-label information. Its improvement plan described website changes and a review of labeling systems; it recorded the pharmacy’s notification of improvements in February 2026. Care delivered remotely still depends on ordinary, exacting work.
The UK business also supplies clinical and technology services for SheMed and HeMed and provides primary care through GP at hand. That breadth makes clear instructions about who supplies which service especially important. A smooth app cannot compensate for a patient misunderstanding where to seek help.
07 / What travels beyond eMed
The lesson is practical: find the point where people struggle to finish a useful task, then put assistance there. Employers can copy the discipline of piloting a benefit before expanding it. Buyers can compare total recurring prices, follow-up access and outcomes measured over the same period.
The approach needs affordable treatment, eligible patients and support people will use. If any of those disappear, reminders cannot repair the economics or the clinical fit. eMed’s wager is that the space after a prescription contains enough unfinished work to build a business. The next proof will come from how well patients keep receiving care.